Santiago Esteban, PhD (Chief Executive Officer)
Dr. Esteban got his Ph.D in chemistry at the Institute of Molecular Science (Valencia, Spain). He has worked in several international institutions (KIT, Groningen Institute of Biotechnology, IRB, BSC) and has become an expert in hard to drug therapeutic targets i.e. IDPs. Dr. Esteban has managed IDP Pharma since its foundation.
Laura Nevola, PhD (Chief Scientific Officer)
Dr. Nevola received her degree in medicinal chemistry and Ph.D in Pharmaceutical Science from the University of Rome “Sapienza” (Italy). After her stay at the laboratory of Prof. Dr. Hamilton at Yale University (USA) she moved to the Institute for Research in Biomedicine (IRB Barcelona). She has designed several de novo drugs and led drug discovery projects.
Raúl Insa, MD, PhD, MBA (Chief Development Officer)
CEO and founder of SOM Biotech. Dr. Insa has managed the development of products from discovery to clinical and out-licensing stages. He acummulates more than 30 years of experience in the pharmaceutical sector and he has held senior positions in multinational pharmaceutical companies such as Parke-Davis (Pfizer), UCB Pharma, Uriach Group (Palau Pharma) and ISDIN (Esteve Group).
Jordi Petit Salamó, MBA (Chief Financial Officer)
Mr. Petit (MBA, ESADE) has a broad experience in corporate finance, venture capital and in the financial area of startups, SMEs, multinationals and large companies. He has worked during more than 25 years in different financial directive positions (Betne, Bull Europe, KPMG, Caixa Capital Risc), including biotech companies (Oryzon Genomics).